Sartorius Stedim Biotech Shows Steady Growth Amid Tariff Adjustments

Sartorius Stedim Biotech continues to show positive business development as it reports its half-year results for 2026. The company achieved sales revenue of 1,527 million euros, marking a 6.4 percent increase in constant currencies. A notable rise was seen in the recurring business with consumables and a mild upswing in bioprocessing equipment sales.

The firm's underlying EBITDA reached 479 million euros, with a margin increase to 31.4 percent. Net profit surged to 181 million euros. These results, however, were affected by U.S. tariff refunds, impacting the reported figures.

All regions contributed positively to the outcomes, with Asia/Pacific leading with a 12.5 percent growth. Sartorius also launched new products, including the Ambr 250 HT Cell Therapies Vessel, enhancing its portfolio in biologics manufacturing.

Looking ahead, Sartorius Stedim Biotech maintains its confidence in meeting its fiscal 2026 targets, notwithstanding uncertainties in the geopolitical landscape and tariff impacts.